BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)

The contract, titled BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003), is aimed at advancing research and development for a nebulization therapy designed to prevent and treat pulmonary foam induced by inhaled chemical agents. The effort focuses on early-stage formulation and analytical development of the drug product, characterization of the nebulizer system including flow rates and particle size distribution, and bioanalytical method development to support non-GLP studies such as pharmacokinetics, dose range finding, and proof-of-concept exposure to chlorine. A critical objective is to generate the data and regulatory strategy required to secure alignment from the FDA during an initial regulatory meeting, with the goal of advancing the technical readiness level to TRL 5 to meet baseline requirements for future contracting opportunities. Outcomes from this phase will directly inform the design and scope of subsequent development stages. This award is managed by the Biomedical Advanced Research and Development Authority within the Department of Health and Human Services, with the primary point of contact located in Washington, D.C., and the performance of work taking place in Minneapolis, Minnesota. The contract was posted on April 27, 2026, under NAICS code 541714 for research and development in the physical, engineering, and life sciences. Funding and oversight are coordinated through BARDA’s DRIVe initiative, and all inquiries should be directed to the designated team at DRIVeAcquisitions@hhs.gov or Richard Hall at Richard.Hall@hhs.gov. The successful execution of this contract is intended to lay the groundwork for future development of a medical countermeasure against chemical agent-induced pulmonary injury.